NEW YORK, December 28, 2025, 23:32 ET — Market closed.
- Pfizer shares closed up 0.24% on Friday at $25.09. [1]
- Investors are focused on the drugmaker’s 2026 outlook and the next quarterly update on Feb. 3. [2]
- The stock is trading within a 52-week range of $20.92 to $27.69. [3]
Pfizer Inc shares edged higher in the last U.S. session, closing Friday up 0.24% at $25.09. The stock traded between $24.92 and $25.11 on the day. [4]
The modest move leaves Pfizer in the mid-$20s, as investors weigh whether the drugmaker can stabilize revenue after a December reset of expectations for 2026. The next scheduled catalyst is the company’s Feb. 3 quarterly update. [5]
Pfizer said on Dec. 16 it expects 2026 revenue of $59.5 billion to $62.5 billion and adjusted diluted earnings of $2.80 to $3.00 per share. “Adjusted” earnings exclude certain items, and the company said the outlook bakes in about $1.5 billion less revenue from its COVID products and about $1.5 billion of headwinds from products losing exclusivity — when patents expire and generic competition typically follows. [6]
Reuters reported the company also warned the next few years would be “bumpy,” citing lower COVID sales, price cuts promised to the U.S. government and patent expirations on key drugs. Pfizer does not expect to return to revenue growth until 2029, the report said. [7]
“This stock is unlikely to break out of its current mid-20s price range until investors are convinced of a growth trajectory,” Bernstein analyst Courtney Breen said. [8]
Pfizer has said it is targeting more than $7 billion in annual cost savings through 2027 as it tries to protect margins while rebuilding growth drivers. The company also expects 4% operational revenue growth at the midpoint of its 2026 guidance, excluding COVID products and those set to lose patent protection. [9]
On the pipeline front, Pfizer and Astellas said on Dec. 17 that a Phase 3 trial of Padcev combined with Merck’s Keytruda met its main goal and improved event-free and overall survival in muscle-invasive bladder cancer. Padcev is an antibody-drug conjugate — a targeted therapy designed to deliver chemotherapy directly to cancer cells. [10]
Pfizer has also faced scrutiny after it said a patient in a long-term study of its hemophilia drug Hympavzi died following a stroke and subsequent brain hemorrhage. The company said it does not expect the incident to affect the drug’s safety profile based on current data and is working with investigators to review the case. [11]
Income-focused investors are tracking Pfizer’s dividend calendar as well. Pfizer said on Dec. 12 its board declared a first-quarter 2026 dividend of 43 cents a share, payable March 6 to shareholders of record as of Jan. 23. [12]
The broader market was little changed in the last session, with the S&P 500 down 0.03% and the Nasdaq down 0.09%, while the Dow was roughly flat. The U.S. 10-year yield stood around 4.14%, according to Investing.com data. [13]
Before the next session, investors have one key date on the calendar: Pfizer’s fourth-quarter and full-year 2025 performance report, due the morning of Feb. 3, followed by a conference call at 10 a.m. EST, the company said. [14]
Traders will be listening for any update to assumptions around Comirnaty and Paxlovid demand, and for detail on how Pfizer plans to offset the revenue headwinds it flagged from fading COVID sales and upcoming loss of exclusivity. [15]
For now, the stock remains in range: its 52-week high is $27.69 and its low is $20.92, while it ended Friday at $25.09. A break outside those levels would mark a clearer shift in sentiment. [16]
References
1. www.investing.com, 2. www.pfizer.com, 3. www.investing.com, 4. www.investing.com, 5. www.pfizer.com, 6. www.pfizer.com, 7. www.reuters.com, 8. www.reuters.com, 9. www.reuters.com, 10. www.pfizer.com, 11. www.reuters.com, 12. www.pfizer.com, 13. www.investing.com, 14. www.pfizer.com, 15. www.reuters.com, 16. www.investing.com
